Evidence map›Paper›PMID 39588344›Full record

ArticleFrontiers in endocrinology2024

Reduced expression of

Erika Urbano De Lima, Filipe Ferreira Dos Santos, Igor Campos Da Silva, Cláudio Rogério Alves De Lima, Vitoria Sousa Frutuoso, Gustavo Felisola Caso, Paloma Ramos De Oliveira, Ana Karina Bezerra, Janete Maria Cerutti, Rodrigo Esaki Tamura and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Erika Urbano De LimaLaboratório de Ciências Moleculares da Tireoide (LCMT) e Laboratório de Biologia Molecular do Câncer (LBMC), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Filipe Ferreira Dos SantosCentro de Oncologia Molecular (MOC), Hospital Sírio-Libanês - Instituto de Ensino e Pesquisa (HSL-IEP), São Paulo, Brazil.
Igor Campos Da SilvaDepartamento de Cirurgia de Cabeça e Pescoço, Monte Tabor - Hospital São Rafael, Salvador, Brazil.
Cláudio Rogério Alves De LimaDepartamento de Cirurgia de Cabeça e Pescoço, Monte Tabor - Hospital São Rafael, Salvador, Brazil.
Vitoria Sousa FrutuosoLaboratório de Ciências Moleculares da Tireoide (LCMT) e Laboratório de Biologia Molecular do Câncer (LBMC), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Gustavo Felisola CasoLaboratório de Ciências Moleculares da Tireoide (LCMT) e Laboratório de Biologia Molecular do Câncer (LBMC), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Paloma Ramos De OliveiraLaboratório de Ciências Moleculares da Tireoide (LCMT) e Laboratório de Biologia Molecular do Câncer (LBMC), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Ana Karina BezerraUniversidade de Fortaleza - Unifor, Fortaleza, Brazil.
Janete Maria CeruttiLaboratório de Bases Genéticas dos Tumores da Tiroide, Departamento de Morfologia e Genética Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Rodrigo Esaki TamuraLaboratório de Ciências Moleculares da Tireoide (LCMT) e Laboratório de Biologia Molecular do Câncer (LBMC), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Helton Estrela RamosLaboratório de Estudos da Tireoide, Departamento de Bioregulação, Universidade Federal da Bahia (UFBA), Salvador, Brazil.
Ileana Gabriela Sanchez de RubioLaboratório de Ciências Moleculares da Tireoide (LCMT) e Laboratório de Biologia Molecular do Câncer (LBMC), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Forkhead box E1 ( Methods: A total of 33 pairs of matched samples of PTC tumors and non-tumors were included. Tumor cell cultures were treated with either 5-Aza-2'-deoxycytidine demethylating agent or dimethyl sulfoxide (DMSO). A real-time polymerase chain reaction (RT-PCR) and Western blotting were performed to assess FOXE1 expression. The methylation status was quantified using bisulfite sequencing. A luciferase gene assay was used to determine CpG-island functionality. Gene expression and promoter methylation of FOXE1 and FOXE1-regulated genes were also analyzed with data from The Cancer Genome Atlas (TCGA) thyroid samples. Results: After demethylating treatment, increased Conclusion:

Indexed as

CpG IslandsDNA MethylationForkhead Transcription FactorsGene Expression Regulation, NeoplasticPromoter Regions, GeneticThyroid NeoplasmsAdultAgedBiomarkers, TumorCell Line, TumorClinical RelevanceDown-RegulationFemaleHumansMaleMiddle AgedBiomarkers, TumorForkhead Transcription FactorsFOXE1 protein, humanaggressivenessdifferentiated thyroid cancerDNA methylationexpressionFOXE1

Identifiers

PMID39588344
PMCPMC11586194

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.